• AAV Parkinson's Disease Tools


    Vigene has partnered with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to distribute AAV viral vectors that can be used for critical research tools to study the underlying mechanisms of Parkinson’s disease. We offer Parkinson’s disease tools that knockdown wild-type and mutant forms of alpha-Synuclein (aSyn), as well as an A53T aSyn viral vector that overexpresses the mutation associated with familial Parkinson’s disease. Our AAV tools for Parkinson’s disease are available immediately and are delivered to you ready for in vitro or in vivo research.

    Research Tools for Parkinson's Disease

    Vector Name

    Description

    aSyn Knockdown Viral Vectors

    AAV1/2-CAG-Human-SNCA-3xmiR/GFP-WPRE-BGH-polyA

    Viral vector encoding GFP and 3xmiR that targets wild-type human aSyn as well as common pathogenic mutants (A53T, A30P, E46K).

    AAV1/2-CAG-Mouse-SNCA-3xmiR/GFP-WPRE-BGH-polyA

    Viral vector encoding GFP and 3xmiR that targets wild-type mouse aSyn as well as common pathogenic mutants (A53T, A30P, E46K).

    AAV1/2-CAG-Scrambled-Control-3xSCRmiR/GFP-WPRE-BGH-polyA

    Scrambled control generated in parallel to above two vectors to use as a control for aSyn knockdown experiments.

    aSyn Overexpression Viral Vectors

    AAV1/2-CMV/CBA-human-A53T-alpha-synuclein-WPRE-BGH-polyA

    Viral vector encoding the human A53T mutation of alpha-synuclein (linked to familial forms of Parkinson’s Disease).

    AAV1/2-CMV/CBA-Null/Empty-WPRE-BGH-polyA

    Empty vector control generated in parallel to the above viral vector to use as a control.

    Click here to place an order for the viral vectors listed in the table above.

    You can also see the FAQ section at the bottom of this page for citations and validation data.


    The MJFF Preclinical Research Tools Program

    MJFF logo

    To aid Parkinson’s research and accelerate the development of effective therapies, MJFF invests in the generation and availability of tools for Parkinson’s disease investigators. MJFF has a multi-faceted approach to developing these research tools. MJFF identifies critical needs through discussions with key scientific experts, generates tools through partnerships with leading experts and companies, evaluates these resources for quality control, and distributes the tools broadly through vendors and partner organizations.


    MJFF Parkinson’s Disease Tools Advantages

    For more information, please visit the MJFF Research Tools page.


    How is Alpha-Synuclein Related to Parkinson’s Disease?

    Alpha-Synuclein (aSyn) is a protein whose function in the healthy brain is currently not well understood. However, aSyn is of great interest to Parkinson's researchers because it is a major component of Lewy bodies, which are protein clumps that are the pathological hallmark of Parkinson's disease. There is compelling evidence from recent studies that aSyn may play a role in the development of both familial (rare) and sporadic (more common) cases of Parkinson’s disease. Currently, various companies are investigating the therapeutic potential of targeting alpha-Synuclein to treat Parkinson’s disease.


    FAQs

    Where can I find more information about these Parkinson’s Disease tools?

    There are currently no publications for the alpha-Synuclein knockdown viral vectors, so please refer to the alpha-Synuclein knockdown validation data sheet. There have been a number of publications using the A53T alpha-Synuclein overexpression viral vectors (see below). You can also refer to the alpha-Synuclein overexpression validation data sheet for more information.

    Ip, C. W. et al. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson’s disease. Acta Neuropathol Commun 5, 11 (2017).

    Koprich, J. B., Johnston, T. H., Reyes, G., Omana, V. & Brotchie, J. M. Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque. PLoS ONE 11, e0167235 (2016).

    Koprich, J. B. et al. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson’s disease produced by decreasing doses of alpha-synuclein. PLoS ONE 6, e17698 (2011).

    Koprich, J. B., Johnston, T. H., Reyes, M. G., Sun, X. & Brotchie, J. M. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson’s disease. Mol Neurodegener 5, 43 (2010).

    Is AAV safe to use?

    Yes. All of our AAV Parkinson’s disease tools are replication-incompetent and can be handled safely in a BSL-1 facility.


    Additional Viral Resources

    Ordering Instructions: Shipping and payment information
    Product Manuals: How to use your virus
    FAQs : Answers to commonly asked questions
    Publications: showcasing Vigene products and services
    Recipient instructions: information on viral safety and storage